Artificial intelligence is becoming increasingly relevant to the development of cancer immunotherapy drugs, and the scale of this field is expected to grow substantially over the next decade. The global AI in cancer immunotherapy drugs sector was valued at USD 2.80 billion in 2025 and is projected to reach approximately USD 27.79 billion by 2035.
The sector is expected to increase from USD 3.52 billion in 2026 to nearly USD 27.79 billion by 2035, representing a compound annual growth rate (CAGR) of 25.80% between 2026 and 2035. This pace of expansion indicates that AI is gaining a stronger role within cancer immunotherapy research and drug development.
Download Report: https://www.precedenceresearch.com/sample/8626
AI in Cancer Immunotherapy Drugs Industry Outlook
The projected increase in the value of the AI in cancer immunotherapy drugs sector reflects growing attention toward the use of artificial intelligence within cancer treatment research.
According to the available projections, the sector will grow from USD 2.80 billion in 2025 to USD 3.52 billion in 2026. By 2035, it is expected to reach approximately USD 27.79 billion.
The projected CAGR of 25.80% from 2026 to 2035 is particularly notable. It suggests that activity in this area is expected to expand at a considerably faster pace over the forecast period. For the healthcare industry, this points to increasing interest in combining AI capabilities with cancer immunotherapy drug development.
Why the Growth Outlook Matters
Cancer immunotherapy has become an important area of healthcare research, while artificial intelligence is increasingly being considered within drug development and related research activities.
The projected figures show that the AI in cancer immunotherapy drugs field is moving beyond a relatively small base. Between 2026 and 2035, the projected increase from USD 3.52 billion to USD 27.79 billion represents a substantial expansion.
For healthcare stakeholders, the main takeaway is the speed of this expected growth. A CAGR of 25.80% indicates that the field could become considerably larger over the coming years, creating greater attention around AI-supported approaches in cancer immunotherapy drug development.
What the Forecast Indicates for the Healthcare Sector
The forecast provides a clear indication of where interest in AI-enabled cancer immunotherapy is heading. The increase from USD 2.80 billion in 2025 to nearly USD 27.79 billion in 2035 reflects strong projected expansion across the decade.
The figures also show that growth is expected to continue after 2026 rather than being concentrated in a single year. This provides a broader view of the potential development of the field and its growing relevance to the healthcare sector.
As AI and cancer immunotherapy continue to intersect, the projected expansion suggests that this area could receive greater attention from researchers, healthcare organizations, and other stakeholders involved in drug development.
Important Points
- The global AI in cancer immunotherapy drugs sector was valued at USD 2.80 billion in 2025.
- Its value is projected to increase to USD 3.52 billion in 2026.
- The sector is expected to reach approximately USD 27.79 billion by 2035.
- A CAGR of 25.80% is projected from 2026 to 2035.
Conclusion
The outlook for AI in cancer immunotherapy drugs points to strong expansion through 2035. From USD 2.80 billion in 2025, the sector is projected to reach approximately USD 27.79 billion by 2035, supported by a forecast CAGR of 25.80%.
While the available data does not explain the specific technologies or applications behind this growth, the numbers clearly show increasing interest in the intersection of artificial intelligence and cancer immunotherapy. Over the coming years, continued development in this field will be an important area to watch within the broader healthcare and drug development landscape.
Buy This Report: https://www.precedenceresearch.com/checkout/8626
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.